<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">World J. Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">WJG</journal-id><journal-title-group><journal-title>World Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">1007-9327</issn><issn pub-type="epub">2219-2840</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27920471</article-id><article-id pub-id-type="pmc">5116594</article-id><article-id pub-id-type="other">jWJG.v22.i43.pg9506</article-id><article-id pub-id-type="doi">10.3748/wjg.v22.i43.9506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Basic Study</subject></subj-group></article-categories><title-group><article-title>Identification of <italic>IL11RA</italic> and <italic>MELK</italic> amplification in gastric cancer by comprehensive genomic profiling of gastric cancer cell lines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Calcagno</surname><given-names>Danielle Queiroz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Takeno</surname><given-names>Sylvia Santomi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gigek</surname><given-names>Carolina Oliveira</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leal</surname><given-names>Mariana Ferreira</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wisnieski</surname><given-names>Fernanda</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Elizabeth Suchi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>Ta&#x000ed;ssa Ma&#x000ed;ra Thomaz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Eleonidas Moura</given-names></name></contrib><contrib contrib-type="author"><name><surname>Melaragno</surname><given-names>Maria Isabel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Demachki</surname><given-names>Samia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>Paulo Pimentel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Burbano</surname><given-names>Rommel Rodriguez</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Mar&#x000ed;lia Cardoso</given-names></name></contrib><aff>Danielle Queiroz Calcagno, Sylvia Santomi Takeno, Carolina Oliveira Gigek, Mariana Ferreira Leal, Fernanda Wisnieski, Elizabeth Suchi Chen, Maria Isabel Melaragno, Mar&#x000ed;lia Cardoso Smith, Disciplina de Gen&#x000e9;tica, Departamento de Morfologia e Gen&#x000e9;tica, Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP 04021-001, Brazil</aff><aff>Danielle Queiroz Calcagno, Ta&#x000ed;ssa Ma&#x000ed;ra Thomaz Ara&#x000fa;jo, Samia Demachki, Paulo Pimentel Assump&#x000e7;&#x000e3;o, Rommel Rodriguez Burbano, N&#x000fa;cleo de Pesquisas em Oncologia, Hospital Universit&#x000e1;rio Jo&#x000e3;o de Barros Barreto, Bel&#x000e9;m, PA 66073-000, Brazil</aff><aff>Sylvia Santomi Takeno, Eleonidas Moura Lima, Departamento de Biologia Molecular, Universidade Federal da Para&#x000ed;ba, Jo&#x000e3;o Pessoa, PB 58051-900, Brazil</aff><aff>Carolina Oliveira Gigek, Disciplina de Gastroenterologia Cir&#x000fa;rgica, Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP 04021-001, Brazil</aff><aff>Mariana Ferreira Leal, Departamento de Ortopedia e Traumatologia, Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP 04021-001, Brazil</aff></contrib-group><author-notes><fn><p>Author contributions: Calcagno DQ and Takeno SS performed the majority of experiments and analyzed the data; Gigek CO, Leal MF, Wisnieski F, Chen ES and Ara&#x000fa;jo TMT performed aCGH investigations; Lima EM performed samples collect; Demachki S made tumor microdissection; Melaragno MI, Burbano RR and Smith MC designed and coordinated the research; Calcagno DQ wrote the paper; Leal MF, Wisnieski F and Assump&#x000e7;&#x000e3;o PP reviewed the paper critically.</p><p>Supported by <funding-source>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo-FAPESP</funding-source>, No. <award-id>2009/07145-9</award-id>.</p><p>Correspondence to: Danielle Queiroz Calcagno, PhD, N&#x000fa;cleo de Pesquisas em Oncologia, Hospital Universit&#x000e1;rio Jo&#x000e3;o de Barros Barreto, Av. Mundurucus, 4487, 1&#x000ba; Piso da Unacon, Bel&#x000e9;m, PA 66073-000, Brazil. <email>danicalcagno@gmail.com</email></p><p>Telephone: +55-91-32016776</p></fn></author-notes><pub-date pub-type="ppub"><day>21</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>11</month><year>2016</year></pub-date><volume>22</volume><issue>43</issue><fpage>9506</fpage><lpage>9514</lpage><history><date date-type="received"><day>15</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><sec><title>AIM</title><p>To identify common copy number alterations on gastric cancer cell lines.</p></sec><sec><title>METHODS</title><p>Four gastric cancer cell lines (ACP02, ACP03, AGP01 and PG100) underwent chromosomal comparative genome hybridization and array comparative genome hybridization. We also confirmed the results by fluorescence <italic>in situ</italic> hybridization analysis using the bacterial artificial chromosome clone and quantitative real time PCR analysis.</p></sec><sec><title>RESULTS</title><p>The amplification of 9p13.3 was detected in all cell lines by both methodologies. An increase in the copy number of 9p13.3 was also confirmed by fluorescence <italic>in situ</italic> hybridization analysis. Moreover, the interleukin 11 receptor alpha (<italic>IL11RA</italic>) and maternal embryonic leucine zipper kinase (<italic>MELK</italic>) genes, which are present in the 9p13.3 amplicon, revealed gains of the <italic>MELK</italic> gene in all the cell lines studied. Additionally, a gain in the copy number of <italic>IL11RA</italic> and <italic>MELK</italic> was observed in 19.1% (13/68) and 55.9% (38/68) of primary gastric adenocarcinoma samples, respectively.</p></sec><sec><title>CONCLUSION</title><p>The characterization of a small gain region at 9p13.3 in gastric cancer cell lines and primary gastric adenocarcinoma samples has revealed <italic>MELK</italic> as a candidate target gene that is possibly related to the development of gastric cancer.</p></sec></abstract><kwd-group><kwd><italic>IL11RA</italic></kwd><kwd>Gastric cancer</kwd><kwd>Genomic profiling</kwd><kwd><italic>MELK</italic></kwd><kwd>9p13.3</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> While the presence of alterations in the DNA copy number is one of the key hallmarks of carcinogenesis, in gastric cancer, the chromosomal regions with frequent gain and loss are still poorly defined. Array comparative genome hybridization is a high resolution tool that allows the simultaneous detection of sub-microscopic copy number changes across the genome. The characterization of a small gain or loss region in gastric cancer cell lines and primary gastric adenocarcinoma samples could reveal a candidate target gene that may possibly be linked to the development of gastric cancer.</p><sec><title>INTRODUCTION</title><p>Gastric cancer (GC) remains a major public health issues, as it is the fifth most common malignancy and the third leading cause of cancer death in both sexes worldwide[<xref rid="B1" ref-type="bibr">1</xref>]. The most common type of GC is adenocarcinoma, which can be further categorized into two main types, intestinal type and diffuse type, which are biologically different with distinct clinical and epidemiological profiles[<xref rid="B2" ref-type="bibr">2</xref>]. The difference in the clinicopathological characteristics between the histological types of gastric cancer indicate that gastric tumor development occurs through the progressive accumulation of distinct genetic alterations[<xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B5" ref-type="bibr">5</xref>]. Thus, the characterization of these genomic abnormalities in gastric cancer may help to clarify the molecular pathogenesis of the disease and may unveil genetic markers of progression and for predicting treatment response or survival.</p><p>Genomic instability with frequent DNA copy number variations (CNVs) is one of the key hallmarks of gastric carcinogenesis[<xref rid="B6" ref-type="bibr">6</xref>]. Tumor progression seems to depend on the successive acquisition of chromosomal aberrations, leading to gains or losses of parts of the genome. However, there is no clear agreement on the genetic changes underlying gastric carcinogenesis.</p><p>In the last decades, chromosomal comparative genome hybridization (cCGH) and array CGH (aCGH) analyses of gastric tumors and gastric cell lines have revealed recurrent DNA CNVs[<xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B11" ref-type="bibr">11</xref>]. Using cCGH, Burbano et al[<xref rid="B3" ref-type="bibr">3</xref>] showed that the copy number gain of 8q24.1, the locus containing the <italic>MYC</italic> oncogene, is a frequent alteration in GC. Further investigations by our group demonstrated that <italic>MYC</italic> amplification is a common finding in preneoplastic gastric lesions and tumors[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B12" ref-type="bibr">12</xref>-<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Moreover, Takeno et al[<xref rid="B10" ref-type="bibr">10</xref>] stated that diffuse-type GC shows a complex pattern of chromosomal alterations, especially chromosome region losses. Recently, Liang et al[<xref rid="B16" ref-type="bibr">16</xref>] suggested that the detection of DNA CNVs from tissue or blood samples may be a useful tool for guiding individualized treatment strategies and for identifying new drug targets in patients with GC.</p><p>In the current study, we analyzed the chromosomal abnormalities of four GC cell lines by cCGH and aCGH. The occurrence of the amplification of chromosomal region 9p13 in GC cell lines was validated by fluorescence <italic>in situ</italic> hybridization (FISH) and confirmed in primary gastric adenocarcinoma samples by quantitative polymerase chain reaction (qPCR). Among the genes within the 9p13 region, we chose two genes for validation in primary GC samples, interleukin 11 receptor alpha (IL11RA) and maternal embryonic leucine zipper kinase (MELK).</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Gastric cancer cell lines</title><p>The ACP02, ACP03 and AGP01 gastric adenocarcinoma cell lines, which were previously established and characterized by our research group, were used in the present study[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>]. Additionally, we used the GC cell line, PG100, obtained from the Rio de Janeiro Cell Bank (Rio de Janeiro, RJ, Brazil), which was previously characterized cytogenetically by our group[<xref rid="B19" ref-type="bibr">19</xref>]. All cell lines were cultured according to Lima et al[<xref rid="B20" ref-type="bibr">20</xref>].</p></sec><sec><title>Primary gastric cancer samples</title><p>Quantitative gene copy number measurements were performed on 68 primary gastric adenocarcinoma samples that were obtained from patients who underwent surgery resection in Jo&#x000e3;o de Barros Barreto University Hospital (HUJBB), Bel&#x000e9;m, Par&#x000e1;, Brazil. In Par&#x000e1;, Brazil, the human population is composed of interethnic crosses between three main origin groups, European (mainly represented by Portuguese), Africans, and Amerindians[<xref rid="B21" ref-type="bibr">21</xref>].</p><p>All the patients had negative histories of exposure to either chemotherapy or radiotherapy before surgery, and there were no other diagnosed cancers. Signed informed consent, with the approval of the ethics committee of HUJBB, was obtained from all patients prior to the collection of samples.</p></sec><sec><title>DNA isolation</title><p>DNA from the GC cells lines and gastric tumors were isolated using the QiAmp DNA isolation kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s recommended protocol. DNA concentration and purity were evaluated by Nanodrop (NanoDrop Technologies, Houston, TX, United States) and agarose gel electrophoresis. All DNA samples used had an A260/280 ratio of 1.8-2.0 and an A260/A230 ratio of &#x0003e; 1.5 and were visualized as a high molecular weight band on an agarose gel.</p></sec><sec><title>cCGH</title><p>DNA samples from GC cell lines were labeled using the CGH Nick Translation Kit (Abbott Laboratories, IL, United States) with Control DNA (Promega, Madison, United States) according to the manufacturer&#x02019;s instructions. Hybridization was performed with CGH Metaphase Target Slides (Abbott Laboratories, Illinois, United States), following the manufacturer&#x02019;s protocols. The slides were analyzed by Corel Photo-Paint - Version 5.00 - Isis Zeiss<sup>&#x000ae;</sup> software, using an Axioskop Zeiss microscope (Carl Zeiss Inc. Canada, Don Mills, ON, Canada) equipped with an epi-illuminator and fluorochrome-specific optical filters.</p><p>The three-color images with red, green, and blue were acquired from 15 metaphases. Chromosome imbalances were detected on the basis of the deviation of the fluorescence ratio profile from the balanced value (FITC:rhodamine = 1). For each chromosome, the final ratio values were prepared from the mean values of at least ten chromosome homologues from separate metaphase spreads. The CGH results were plotted as a series of green to red ratio profiles.</p></sec><sec><title>aCGH</title><p>To evaluate the complete genome of all the four cell lines studied, high density microarray analysis was performed using the AffymetrixR CytoScan&#x02122; HD Array platform (Affymetrix, Santa Clara, CA, United States). First, genomic DNA was digested by the <italic>Nsp</italic>I restriction enzyme, and the digested samples were ligated using the <italic>Nsp</italic>I adaptor. The fragments were amplified by PCR and run on a 2% agarose gel to verify that the PCR product size distribution was between 150 bp and 2000 bp. After PCR product purification and dilution, we performed the quantification of each sample using a NanodropR 1000 Spectophotometer (NanoDrop Technologies, Houston, TX, United States). The average purification yield for each sample was &#x02265; 3.0 &#x003bc;g/&#x003bc;L.</p><p>The purified samples were then fragmented using DNAse I enzyme, and the products were run on a 4% agarose gel to verify that the majority of fragments had a size distribution between 25 and 125 bp.</p><p>Labeling was performed using terminal deoxynucleotidyl transferase enzyme, which adds biotinylated nucleotides at the 3&#x02019; end of fragmented samples.</p><p>During the hybridization step, each sample was hybridized onto a CytoScan<sup>&#x000ae;</sup> HD Array (Affymetrix, Santa Clara, CA, United States) and placed in a GeneChip<sup>&#x000ae;</sup> Hybridization Oven 640 (Affymetrix, Santa Clara, CA, United States) at 50 &#x000b0;C and 60 rpm for 16 to 18 h. The processes prior to scanning of arrays, washing and staining, were carried out at a Fluidics Station 450 (Affymetrix, Santa Clara, CA, United States). The arrays were scanned using GeneChip<sup>&#x000ae;</sup> Scanner 3000 7G (Affymetrix, Santa Clara, CA, United States).</p><p>The copy number was deduced from the weighted log<sub>2</sub> ratio and the aberration type was identified and confirmed using allelic plots.</p></sec><sec><title>FISH</title><p>FISH was performed on nuclei and metaphase spreads of the cell lines, ACP02, ACP03 and AGP01. Metaphase spreads of lymphocytes from a healthy donor were used as a control. The bacterial artificial chromosome (BAC) clone, RP11-165H19, was obtained from <italic>BAC/PAC Resources</italic> (<uri xlink:type="simple" xlink:href="http://bacpac.chori.org/">http://bacpac.chori.org/</uri>). Bacterial cultures and DNA isolation was performed using Qiagen Plasmid Kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s protocol. Alu-PCR products of the BAC were used as probes and were biotinylated using nick translation, as described previously[<xref rid="B22" ref-type="bibr">22</xref>].</p></sec><sec><title>qPCR</title><p>For the validation of 9p13 amplification, we evaluated the copy number of two genes within this locus, <italic>IL11RA</italic> and <italic>MELK</italic>. For this, we used the same DNA samples from GC cell lines that were used for cCGH and aCGH and from GC tissues. qPCR was performed using the FAM/MGB-labeled TaqMan probes (Life Technologies, Foster City, CA, USA) for <italic>IL11RA</italic> (Hs01842695_cn) or <italic>MELK</italic> (Hs05076287_cn). VIC/TAMRA-labeled TaqManCopy Number Reference Assay RNAse P (#4403326; Life Technologies, Foster City, CA, United States) was used as an internal control. All the real-time qPCR reactions were performed in quadruplicate with gDNA using a 7500 Fast Real-Time PCR system (Life Technologies, Foster City, CA, United States) as described previously[<xref rid="B13" ref-type="bibr">13</xref>]. The copy number of each sample was estimated by CNV analysis using Copy Caller Software V1.0 (Life Technologies, Foster City, CA, United States). Known Human Genomic DNA, G1471 and G1521 (Promega, Madison, United States), were used for calibration.</p></sec><sec><title>Statistical analysis</title><p>The data on clinical features were compared by the &#x003c7;<sup>2</sup> test or two-tailed Fisher&#x02019;s exact test for categorical variables. All statistical analyses were performed with the statistical package SPSS for Windows (V.17.0, SPSS Inc, Chicago, IL, United States). <italic>P</italic> values of &#x02264; 0.05 were considered significant.</p></sec></sec><sec><title>RESULTS</title><sec><title>Recurrent regions of alterations</title><p>The ACP02, ACP03, AGP01 and PG100 cell lines showed multiple gains and losses by cCGH and aCGH. Most chromosomal aberrations detected in these cell lines by cCGH were confirmed by aCGH (Table <xref ref-type="table" rid="T1">1</xref>), although aCGH analysis enabled the identification of many additional chromosomal gains and losses. On the other hand, the gain of 16p21-p23 in ACP03 and the gains of 6p11-p12, 12p11.1 and 18p11.2-p11.3 in AGP01 were detected only by cCGH.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Overview of detected chromosomal aberrations by chromosomal comparative genome hybridization and array comparative genome hybridization on gastric cancer cell lines</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Cell line</bold></td><td rowspan="1" colspan="1"><bold>cCGH</bold></td><td rowspan="1" colspan="1"><bold>aCGH</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">ACP02</td><td rowspan="1" colspan="1">+8p21-pter, +8q24, +9p12-p22, +9q21.1-q21.3, +15q11.1-q14, +16p, +16q, +17p11, +17q11.2, +17q23, +22q11.1-q12.3</td><td rowspan="1" colspan="1">+1p13.2, +1p21.3, +1q21.2, +1q21.3, +2p11.2, +4p12, +4p13, +4q12, +5q12.1, +7q11.22, +7q11.23, +8p11.23, +8p21.3, +8q24.11, +8q24.22, -8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, +9p11.3, +9q21.12, +10p11.22, +10p12.1, +10p12.31, +10p13, +10p14, +10q11.21, -11p11.12, +11p11.2, , -11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, +15q11.2, +15q12, +15q14, +15q15.3, +15q24.1, +15q25.1, +15q26.1, +16p11.2, +16p12.3, +16q11.2, +16q13, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +19q13.11, +20p11.1, +20p11.23, +20p12.2, +20q11.21, +20q11.23, +22q11.21,+ 22q11.23, +22q12.2, +22q12.3</td></tr><tr><td align="left" rowspan="1" colspan="1">ACP03</td><td rowspan="1" colspan="1">+4p15.1-pter, +6p22.3-p24, +6q25.1,q26, +8p22-pter, -8q11.1-q11.2, +9p12-p22, +10p12-p14, -11p11.1, -11q12, +15q11.1-q15, +15q23-q26.1, +16p12-p13.1, +16p21-p23, +22q11.1-q12.1</td><td rowspan="1" colspan="1">+1p13.2, +1p13.3, +1p21.3, +1q21.1, +1q21.2, 1q21.3, +2p12, +4p12, +4p14-p13, +4p15.1, +5q12.1, +6p24.2, +7q11.21, +7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.2, +8p21.3, -8q11.21, +8q24.11, -8q24.12, +8q24.13, +8q24.21, +8q24.22, -8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, +9q21.13, +9p23, +10p11.21, +10p11.22, +10p12.1, +10p12.2, +10p12.31, +10p12.33, +10p13, +10p14, +10q11.21, -11p11.12, +11q11.2, -11q12.1-q12.2, -11q12.3, +12q12-q15, +14q11.2, +14q13.2, +15q11.2, +15q12, +15q13.1, +15q14, +15q24.1, +15q25.1, +15q25.2, +15q26.1, +16p11.2, +16p12.3, +16q11.2, +16q12.1, +16q12.2, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +18q12.1, +19q13.11, +20p11.1, +20p11.23, +20p12.2, +20q11.21, +20q11.22, +20q11.23, +22q11.21, +22q11.23, +22q12.2, +22q12.3</td></tr><tr><td align="left" rowspan="1" colspan="1">AGP01</td><td rowspan="1" colspan="1">+1p13-21, +1q12-q21.3, +2p11.2-p12, +4p11-p12, +4q12-q13.1, +5p11-p12, +5q11.2-q12, +6p11-p12, +6q12-q16.1, +7q11.1-q11.2, +9p12-p13, +9q13-q21.3, +10p11.2-p12.3, +10q11.1-q21.1, +11p11-p11.2, +12p11.1, +12q12, +13q11-q12, +14q11.1-q13, +15q11-q14, +16p11.2, +16q12, +17p11.2, +17q11.2, +18p11.2-p11.3, +18q11-q12, +19q12-q13.1, +20p11.2-p12, +20q11.1-q11.2</td><td rowspan="1" colspan="1">+1p13.3, +1p21.3, +1q21.2, +1q21.3, +2p11.2, +2p12, +4p12, +4p14-p13, +5p12, +5q12.1, +6p24.2, +6q13, +7q11.21, +7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.3, -8q11.21, +8q24.11, -8q24.12, +8q24.21, +8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, +9p22.3, +9q21.12, +9q21.13, +10p11.22, +10p12.1, +10p12.31, +10p13, +10p14, +10q11.21, -11p11.12, +11p11.2, -11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, +15q12, +15q14, +15q15.1, +15q15.3, +15q24.1, +15q25.1, +15q25.2, +15q25.3, +15q26.1, +16p11.2, +16p12.3, +16q11.2, +16q12.1, +16q13, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +19q13.11, +20p11.21, +20p11.1, +20p11.23, +20p12.2, 20q11.21, +20q11.23, +22q11.21, +22q11.23, +22q12.2, +22q12.3</td></tr><tr><td align="left" rowspan="1" colspan="1">PG100</td><td rowspan="1" colspan="1">+9p12-p23</td><td rowspan="1" colspan="1">+1p13.2, +1p13.3, +1p21.3, +1q21.1, +1q21.2, +1q21.3, +2p11.2, +4p15.1, +6q13, +7q11.21, +7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.2, +8p21.3, -8q11.21, +8q24.11, +8q24.13, +8q24.22, -8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, +9p22.3, +9q21.12, +9q21.13, +10p11.22, +10p12.1, +10p12.2, +10p12.31, +10p14, +10q11.21, +11p11.2, -11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, +15q11.2, +15q12, +15q14, +15q15.1, +15q15.3, +15q24.1, +15q25.2, +15q25.3, +15q26.1, +16p11.2, +16p12.3, +16q11.2, +16q12.1, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +19q13.11, +20p11.1, +20p11.23, +20p12.2, +20q11.21, +20q11.23, +22q11.21, +22q11.23, +22q12.1-q12.2, +22q12.2, +22q12.3</td></tr></tbody></table><table-wrap-foot><fn><p>cCGH: Chromosomal comparative genome hybridization; aCGH: Array comparative genome hybridization.</p></fn></table-wrap-foot></table-wrap><p>Notably, the gain of chromosome region 9p13 was common in all cell lines and as such, this locus was selected for further investigation.</p></sec><sec><title>Validation of the amplified pericentromeric region, 9p13</title><p>The presence of the 9p13 ampli&#x0fb01;cation in the GC cell lines was confirmed by metaphase FISH using a BAC clone (Figure <xref ref-type="fig" rid="F1">1</xref>). We observed signal gain in all cell lines, and only ACP02 showed high amplification of this region (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>9p13 amplification by fluorescence <italic>in situ</italic> hybridization analysis in ACP02 (A), ACP03 (B) and AGP01 (C) cell lines. Magnification of &#x000d7; 60.</p></caption><graphic xlink:href="WJG-22-9506-g001"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Number of copies of 9q13 locus by FISH analysis in gastric cancer cell lines <italic>n</italic> (%)</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Cell line</bold></td><td rowspan="1" colspan="1"><bold>0 signal</bold></td><td rowspan="1" colspan="1"><bold>1 signal</bold></td><td rowspan="1" colspan="1"><bold>2 signals</bold></td><td rowspan="1" colspan="1"><bold>3 signals</bold></td><td rowspan="1" colspan="1"><bold>4 signals</bold></td><td rowspan="1" colspan="1">&#x02265; <bold>5 signals</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">ACP02</td><td rowspan="1" colspan="1">12 (6.0)</td><td rowspan="1" colspan="1">26 (13.0)</td><td rowspan="1" colspan="1">112 (56.0)</td><td rowspan="1" colspan="1">25 (12.5)</td><td rowspan="1" colspan="1">22 (11.0)</td><td rowspan="1" colspan="1">3 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">ACP03</td><td rowspan="1" colspan="1">22 (11.0)</td><td rowspan="1" colspan="1">40 (20.0)</td><td rowspan="1" colspan="1">99 (49.5)</td><td rowspan="1" colspan="1">22 (11.0)</td><td rowspan="1" colspan="1">6 (3.0)</td><td rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">AGP01</td><td rowspan="1" colspan="1">19 (9.5)</td><td rowspan="1" colspan="1">45 (22.5)</td><td rowspan="1" colspan="1">99 (49.5)</td><td rowspan="1" colspan="1">27 (13.5)</td><td rowspan="1" colspan="1">10 (5.0)</td><td rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">PG100</td><td rowspan="1" colspan="1">18 (9.0)</td><td rowspan="1" colspan="1">55 (27.5)</td><td rowspan="1" colspan="1">87 (43.5)</td><td rowspan="1" colspan="1">32 (16.0)</td><td rowspan="1" colspan="1">7 (3.5)</td><td rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">34 (17.0)</td><td rowspan="1" colspan="1">68 (34.0)</td><td rowspan="1" colspan="1">97 (48.5)</td><td rowspan="1" colspan="1">1 (0.5)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>Based on gene location and annotated gene function, we selected the <italic>MELK</italic> and <italic>IL11RA</italic> genes for validation in GC cell lines and in 68 primary gastric adenocarcinoma by qPCR. We detected two copies of <italic>IL11RA</italic> and three copies of <italic>MELK</italic> in all GC cell lines. By analyzing the CNV of these two genes in gastric tumors, we observed that 19.1% (13/68) and 55.9% (38/68) of gastric tumors had &#x02265; 3 copies of <italic>IL11RA</italic> and <italic>MELK</italic>, respectively. No association was found between the clinicopathological characteristics of patients and the number of copies of the studied genes (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><italic>MELK</italic> and <italic>IL11RA</italic> gene copy number and clinicopathological features of 68 gastric cancer patients</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" rowspan="1"><bold><italic>MELK</italic></bold><hr/></td><td colspan="3" rowspan="1"><bold><italic>IL11RA</italic></bold><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>2 copies (<italic>n</italic> = 38)</bold></td><td rowspan="1" colspan="1">&#x02265; <bold>3 copies (<italic>n</italic> = 30)</bold></td><td rowspan="1" colspan="1"><bold><italic>P</italic> value</bold></td><td rowspan="1" colspan="1"><bold>2 copies (<italic>n</italic> = 55)</bold></td><td rowspan="1" colspan="1">&#x02265; <bold>3 copies (<italic>n</italic> = 13)</bold></td><td rowspan="1" colspan="1"><bold><italic>P</italic> value</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Age (yr) (mean &#x000b1; SD)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e; 50 (64.5 &#x000b1; 6.9)</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0.0748</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0.7461</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02264; 50 (42.5 &#x000b1; 5.2)</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">0.5781</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0.7544</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histopathology</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intestinal</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">0.7886</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0.1110</td></tr><tr><td align="left" rowspan="1" colspan="1">Diffuse</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Depth of tumor invasion</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">pT1-pT2</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0.5137</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0.4076</td></tr><tr><td align="left" rowspan="1" colspan="1">pT3-pT4</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lymph node metastasis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1.0000</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0.1091</td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">I-II</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">0.6049</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0.7525</td></tr><tr><td align="left" rowspan="1" colspan="1">III-IV</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec></sec><sec><title>DISCUSSION</title><p>aCGH is a high resolution tool that allows the simultaneous detection of sub-microscopic copy number changes across the genome, thus overcoming the several limitations of cCHG[<xref rid="B23" ref-type="bibr">23</xref>]. In this study, most of the copy number changes observed in ACP02, ACP03, AGP01 and PG100 by cCGH were confirmed by aCGH. ACP02, ACP03 and AGP01 are gastric adenocarcinoma cell lines from diffuse and intestinal types and cancerous ascitic fluid and were previously established and characterized by our research group[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>], while PG100 is a commercially available primary gastric adenocarcinoma cell line[<xref rid="B19" ref-type="bibr">19</xref>]. Furthermore, aCGH analysis enabled the identification of many additional chromosomal gains and losses. On the other hand, the gain of the 16p21-p23 region in ACP03 and the gains of the 6p11-p12, 12p11.1 and 18p11.2-p11.3 regions in AGP01 were only detected by cCGH. This may be due to technical reasons, as cCGH is more sensitive than aCGH for detecting large chromosome regions, as previously discussed by Kamradt et al[<xref rid="B24" ref-type="bibr">24</xref>].</p><p>When comparing the GC cell lines, only a few differences in cytogenetic composition were found by cCGH and aCGH. The gain on 9p13.3 was found in all cell lines, and the presence of this amplicon in these gastric cell lines was confirmed by metaphase FISH, using a BAC clone for the amplified region. It is noteworthy that high levels of this amplification were only found in ACP02.</p><p>Genetic alterations in the short arm of chromosome 9 are commonly observed in different cancer types[<xref rid="B25" ref-type="bibr">25</xref>]. In GC, losses of 9p have been frequently described[<xref rid="B26" ref-type="bibr">26</xref>-<xref rid="B29" ref-type="bibr">29</xref>]. Fan et al[<xref rid="B29" ref-type="bibr">29</xref>] (2012) observed a homozygous deletion at 9p21, which encompasses the <italic>P16INK4A</italic> tumor suppressor gene, in 11% (8/72) of the gastric tumors studied. To our knowledge, this is the first study that describes gains at 9p in GC.</p><p>Amplifications on 9p have been reported in esophageal cancer[<xref rid="B30" ref-type="bibr">30</xref>], lung sarcomatoid carcinoma[<xref rid="B31" ref-type="bibr">31</xref>] and breast cancer[<xref rid="B32" ref-type="bibr">32</xref>]. Towle et al[<xref rid="B33" ref-type="bibr">33</xref>] found that 16.6% (36/217) of the cell lines carried regions of genomic gain spanning part of chromosome 9p13. Additionally, 1.8% (4/217) harbored high-level DNA amplification of this region, including a ductal breast carcinoma line (B0T-474), a tongue squamous cell carcinoma line (SCC-9), a melanoma line (WM-115), and an osteosarcoma line (MG-63).</p><p>Because this region harbors several tumor-related genes, several studies in the literature have correlated gene copy number alterations of 9p13 with cancer[<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B34" ref-type="bibr">34</xref>]. Sarhadi et al[<xref rid="B34" ref-type="bibr">34</xref>] observed that the gain of chromosome 9p13 encompasses many genes, such as <italic>KIAA1161</italic>, <italic>C9orf24</italic>, <italic>C9orf25</italic>, <italic>DNAI1</italic>, <italic>ENHO</italic>, <italic>CNTFR</italic>, <italic>LOC415056</italic>, <italic>C9orf23</italic>, <italic>DCTN3</italic>, <italic>ARID3C</italic>, <italic>SIGMAR1</italic>, <italic>GALT</italic>, <italic>IL11RA</italic>, <italic>CCL27</italic>, <italic>CCL19</italic>, <italic>CCL21</italic> and <italic>FAM205A</italic>, in different types of cancer.</p><p>In this study, we selected the <italic>IL11RA</italic> and <italic>MELK</italic> genes to validate this amplification region in GC cell lines and primary gastric adenocarcinoma. The results showed an increase in the copy number of the <italic>MELK</italic> gene in ACP02, ACP03, AGP01 and PG100. Moreover, 19.1% (13/68) and 55.9% (38/68) of gastric tumors showed &#x02265; 3 copies of <italic>IL11RA</italic> and <italic>MELK</italic>, respectively.</p><p>Kamradt et al[<xref rid="B24" ref-type="bibr">24</xref>] analyzed a small amplicon at 9p13.3 in prostate cancer cell lines and validated <italic>IL11RA</italic> copy number gain in 75% (15/20) of prostate tumors. In addition, it has been demonstrated that <italic>IL11RA</italic> is overexpressed in GC, colon cancer, breast cancer, prostate cancer and osteosarcoma[<xref rid="B35" ref-type="bibr">35</xref>-<xref rid="B41" ref-type="bibr">41</xref>]. <italic>IL11RA</italic> encodes a specific receptor for IL11, and the IL11/IL11RA signaling pathway is involved in the regulation of several biological activities, such as adipogenesis, osteoclastogenesis, neurogenesis, and megakaryocyte maturation and platelet production[<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>].</p><p>With regard to <italic>MELK</italic>, the other gene that was selected for validation, this study describes, for the first time, that the copy number gain of the <italic>MELK</italic> gene occurs in cancer. To our knowledge, only one previous study on astrocytoma samples has investigated <italic>MELK</italic> amplification, and they did not find any <italic>MELK</italic> copy number gain[<xref rid="B44" ref-type="bibr">44</xref>].</p><p>MELK is a highly conserved serine/threonine kinase that was first found to be expressed in a wide range of early embryonic cellular stages, and as a result, it has been implicated in embryogenesis and cell cycle control[<xref rid="B45" ref-type="bibr">45</xref>]. Additionally, several studies have identified MELK overexpression in stem cell populations and several human cancers, including aggressive astrocytoma, breast cancer, prostate cancer, melanoma and GC[<xref rid="B44" ref-type="bibr">44</xref>-<xref rid="B49" ref-type="bibr">49</xref>].</p><p>Preclinical studies have suggested MELK as a potential therapeutic target for multiple cancers. Since then, novel therapeutics that selectively inhibit MELK have been developed, such as OTSSP167, which is currently in a Phase I trial for patients with solid tumors and who have not responded to treatment[<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B50" ref-type="bibr">50</xref>-<xref rid="B53" ref-type="bibr">53</xref>].</p><p>Li et al[<xref rid="B54" ref-type="bibr">54</xref>] observed MELK overexpression more frequently in GC lesions than in the corresponding noncancerous mucosa and that higher MELK levels were associated with lymph node involvement, distant metastasis, and poor prognosis in patients with GC. In addition, these authors demonstrated that reducing MELK expression or inhibiting its kinase activity resulted in growth inhibition, G2/M arrest, apoptosis and the suppression of the invasive capability of GC cells <italic>in vitro</italic> and <italic>in vivo</italic>. <italic>MELK</italic> knockdown also led to alterations in the levels of epithelial mesenchymal transition (EMT)-associated proteins. Furthermore, in GC patient-derived xenograft models, targeted treatment with OTSSP167 showed anticancer effects. These results suggest that MELK may be a promising target for GC treatment.</p><p>In conclusion, our results from generating genome wide DNA copy number profiles in GC cell lines and validation in primary gastric adenocarcinoma specimens revealed genomic aberrations redundancies, indicating that the cell lines retain the gross genomic architecture of primary tumors. Moreover, the characterization of a small gained region at 9p13.3 in GC cell lines and primary gastric adenocarcinoma samples revealed <italic>MELK</italic> as a candidate target gene this region that may possibly be linked to the development of GC. Therefore, we hypothesize that the copy number gain of <italic>MELK</italic> may be a mechanism of gene overexpression and may represent an interesting therapeutic target in gastric carcinogenesis.</p></sec><sec><title>COMMENTS</title><sec><title>Background</title><p>Despite alterations in DNA copy number is one of the key hallmarks of carcinogenesis, the chromosomal regions with frequent gain and loss are still poorly defined in gastric cancer. The characterization of a small gain or loss region in gastric cancer cell lines and primary gastric adenocarcinoma samples could reveal a candidate target gene that may possibly be linked to the development of gastric cancer.</p></sec><sec><title>Research frontiers</title><p>DNA copy number profiles in gastric cancer cell lines and validation in primary gastric adenocarcinoma specimens revealed genomic aberrations redundancies, indicating that the cell lines retain the gross genomic architecture of primary tumors. Moreover, the characterization of a small gained region at 9p13.3 in gastric cancer cell lines and primary gastric adenocarcinoma samples revealed <italic>MELK</italic> as a candidate target gene that is possibly related to the development of gastric cancer.</p></sec><sec><title>Innovations and breakthroughs</title><p>Several studies in the literature have correlated gene copy number alterations of 9p13 region. A study described a small amplicon at 9p13.3 in prostate cancer cell lines and validated <italic>IL11RA</italic> copy number gain in 75% (15/20) of prostate tumors. However, this is the first time that the copy number gain of the <italic>MELK</italic> gene was described in tumor. Furthermore, in gastric cancer patient-derived xenograft models, targeted treatment with OTSSP167 (a MELK inhibitor) showed anticancer effects. These results suggest that MELK may be a promising target for gastric cancer treatment.</p></sec><sec><title>Applications</title><p>The authors suggested that the copy number gain of <italic>MELK</italic> may be a mechanism of gene overexpression and may represent an interesting therapeutic target in gastric carcinogenesis in the future.</p></sec><sec><title>Terminology</title><p>Copy number variation (CNV) is a type of structural variation characterized by duplication or deletion of sections of the genome, which in turn can result in phenotypic alterations. Array comparative genomic hybridization (aCGH) is a technology developed for a high-resolution evaluation of DNA copy number alterations associated with chromosome abnormalities.</p></sec><sec><title>Peer-review</title><p>The authors tried to identify common copy number alterations by using chromosomal comparative genome hybridization and array comparative genome hybridization in four gastric cancer cell lines. They concluded MELK as a candidate target gene that is possibly related to the development of gastric cancer.</p></sec></sec></body><back><fn-group><fn><p>Manuscript source: Invited manuscript</p></fn><fn><p>Specialty type: Gastroenterology and hepatology</p></fn><fn><p>Country of origin: Brazil</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): B</p></fn><fn><p>Grade C (Good): 0</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn><p>Institutional review board statement: All specimens were taken after informed consente and ethical permission was obtained for participation in the study. The study was reviewed and approved by the HUJBB Institutional Review Board.</p></fn><fn fn-type="COI-statement"><p>Conflict-of-interest statement: The authors declare that there is no conflict of interests regarding the publication of this article.</p></fn><fn><p>Data sharing statement: No additional data are available.</p></fn><fn><p>Peer-review started: July 16, 2016</p></fn><fn><p>First decision: August 19, 2016</p></fn><fn><p>Article in press: October 10, 2016</p></fn><fn><p>P- Reviewer: Kupeli S S- Editor: Qi Y L- Editor: A E- Editor: Wang CH</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Globocan</surname><given-names>2012</given-names></name></person-group><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr">http://globocan.iarc.fr</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauren</surname><given-names>P</given-names></name></person-group><article-title>The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification</article-title><source>Acta Pathol Microbiol Scand</source><year>1965</year><volume>64</volume><fpage>31</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">14320675</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burbano</surname><given-names>RR</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Takeno</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>ES</given-names></name><name><surname>De Arruda Cardoso Smith</surname><given-names>M</given-names></name></person-group><article-title>C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil</article-title><source>Anticancer Res</source><year>2006</year><volume>26</volume><fpage>2909</fpage><lpage>2914</lpage><pub-id pub-id-type="pmid">16886612</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Taken</surname><given-names>SS</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Demachki</surname><given-names>S</given-names></name><name><surname>Smith Mde</surname><given-names>A</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma</article-title><source>Anticancer Res</source><year>2005</year><volume>25</volume><fpage>4069</fpage><lpage>4074</lpage><pub-id pub-id-type="pmid">16309200</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Seabra</surname><given-names>AD</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Pontes</surname><given-names>TB</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>De Arruda Cardoso Smith</surname><given-names>M</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>MYC insertions in diffuse-type gastric adenocarcinoma</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><fpage>2479</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">19596917</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panani</surname><given-names>AD</given-names></name></person-group><article-title>Cytogenetic and molecular aspects of gastric cancer: clinical implications</article-title><source>Cancer Lett</source><year>2008</year><volume>266</volume><fpage>99</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">18381231</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>KC</given-names></name><name><surname>Shin</surname><given-names>SY</given-names></name><name><surname>Jeon</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Noh</surname><given-names>SM</given-names></name></person-group><article-title>Genetic alterations of gastric cancer: comparative genomic hybridization and fluorescence In situ hybridization studies</article-title><source>Cancer Genet Cytogenet</source><year>2000</year><volume>117</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">10704677</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>MS</given-names></name><name><surname>Chang</surname><given-names>MC</given-names></name><name><surname>Huang</surname><given-names>SP</given-names></name><name><surname>Tseng</surname><given-names>CC</given-names></name><name><surname>Sheu</surname><given-names>JC</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Shun</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name></person-group><article-title>Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer</article-title><source>Genes Chromosomes Cancer</source><year>2001</year><volume>30</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11107179</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Kashima</surname><given-names>K</given-names></name><name><surname>Daa</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name></person-group><article-title>Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression</article-title><source>Mod Pathol</source><year>2004</year><volume>17</volume><fpage>1328</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">15154013</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeno</surname><given-names>SS</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Lisboa</surname><given-names>LC</given-names></name><name><surname>Lipay</surname><given-names>MV</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name><name><surname>Smith Mde</surname><given-names>A</given-names></name></person-group><article-title>Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization</article-title><source>Cancer Genet Cytogenet</source><year>2009</year><volume>190</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19264226</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seabra</surname><given-names>AD</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>TM</given-names></name><name><surname>Mello Junior</surname><given-names>FA</given-names></name><name><surname>Di Felipe &#x000c1;vila Alc&#x000e2;ntara</surname><given-names>D</given-names></name><name><surname>De Barros</surname><given-names>AP</given-names></name><name><surname>De Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Montenegro</surname><given-names>RC</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name><name><surname>Demachki</surname><given-names>S</given-names></name><name><surname>Burbano</surname><given-names>RM</given-names></name><etal/></person-group><article-title>High-density array comparative genomic hybridization detects novel copy number alterations in gastric adenocarcinoma</article-title><source>Anticancer Res</source><year>2014</year><volume>34</volume><fpage>6405</fpage><lpage>6415</lpage><pub-id pub-id-type="pmid">25368240</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Seabra</surname><given-names>AD</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>ES</given-names></name><name><surname>Demachki</surname><given-names>S</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Faria</surname><given-names>MH</given-names></name><name><surname>Rabenhorst</surname><given-names>SH</given-names></name><name><surname>Ferreira</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>6207</fpage><lpage>6211</lpage><pub-id pub-id-type="pmid">17036397</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Freitas</surname><given-names>VM</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>de Souza</surname><given-names>CR</given-names></name><name><surname>Demachki</surname><given-names>S</given-names></name><name><surname>Montenegro</surname><given-names>R</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Smith Mde</surname><given-names>A</given-names></name><name><surname>dos Santos</surname><given-names>AK</given-names></name><etal/></person-group><article-title>MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer</article-title><source>BMC Gastroenterol</source><year>2013</year><volume>13</volume><fpage>141</fpage><pub-id pub-id-type="pmid">24053468</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Souza</surname><given-names>CR</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Costa Sozinho</surname><given-names>EK</given-names></name><name><surname>Borges Bdo</surname><given-names>N</given-names></name><name><surname>Montenegro</surname><given-names>RC</given-names></name><name><surname>Dos Santos</surname><given-names>AK</given-names></name><name><surname>Dos Santos</surname><given-names>SE</given-names></name><name><surname>Ribeiro</surname><given-names>HF</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><etal/></person-group><article-title>MYC deregulation in gastric cancer and its clinicopathological implications</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e64420</fpage><pub-id pub-id-type="pmid">23717612</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa Raiol</surname><given-names>LC</given-names></name><name><surname>Figueira Silva</surname><given-names>EC</given-names></name><name><surname>Mendes da Fonseca</surname><given-names>D</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>de Arruda Cardoso Smith</surname><given-names>M</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma</article-title><source>Cancer Genet Cytogenet</source><year>2008</year><volume>181</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">18262050</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>JY</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>1475</fpage><lpage>1482</lpage><pub-id pub-id-type="pmid">26073079</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Martins do Nascimento</surname><given-names>JL</given-names></name><name><surname>da Silva</surname><given-names>CE</given-names></name><name><surname>Vita Lamar&#x000e3;o</surname><given-names>MF</given-names></name><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Cabral</surname><given-names>IR</given-names></name><name><surname>de Arruda Cardoso Smith</surname><given-names>M</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>Establishment and conventional cytogenetic characterization of three gastric cancer cell lines</article-title><source>Cancer Genet Cytogenet</source><year>2009</year><volume>195</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">19837275</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Calcagno</surname><given-names>DQ</given-names></name><name><surname>Borges da Costa Jde</surname><given-names>F</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Khayat</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>ES</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>de Arruda Cardoso Smith</surname><given-names>M</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors</article-title><source>J Biomed Biotechnol</source><year>2011</year><volume>2011</volume><fpage>631268</fpage><pub-id pub-id-type="pmid">21528007</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>HF</given-names></name><name><surname>Alc&#x000e2;ntara</surname><given-names>DF</given-names></name><name><surname>Matos</surname><given-names>LA</given-names></name><name><surname>Sousa</surname><given-names>JM</given-names></name><name><surname>Leal</surname><given-names>MF</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name><name><surname>Bahia</surname><given-names>MO</given-names></name></person-group><article-title>Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line</article-title><source>Braz J Med Biol Res</source><year>2010</year><volume>43</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">20658094</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>EM</given-names></name><name><surname>Rissino</surname><given-names>JD</given-names></name><name><surname>Harada</surname><given-names>ML</given-names></name><name><surname>Assump&#x000e7;&#x000e3;o</surname><given-names>PP</given-names></name><name><surname>Demachki</surname><given-names>S</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name><name><surname>Casartelli</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Burbano</surname><given-names>RR</given-names></name></person-group><article-title>Conventional cytogenetic characterization of a new cell line, ACP01, established from a primary human gastric tumor</article-title><source>Braz J Med Biol Res</source><year>2004</year><volume>37</volume><fpage>1831</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">15558189</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista dos Santos</surname><given-names>SE</given-names></name><name><surname>Rodrigues</surname><given-names>JD</given-names></name><name><surname>Ribeiro-dos-Santos</surname><given-names>AK</given-names></name><name><surname>Zago</surname><given-names>MA</given-names></name></person-group><article-title>Differential contribution of indigenous men and women to the formation of an urban population in the Amazon region as revealed by mtDNA and Y-DNA</article-title><source>Am J Phys Anthropol</source><year>1999</year><volume>109</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">10378456</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulikowski</surname><given-names>LD</given-names></name><name><surname>Bellucco</surname><given-names>FT</given-names></name><name><surname>Nogueira</surname><given-names>SI</given-names></name><name><surname>Christofolini</surname><given-names>DM</given-names></name><name><surname>Smith Mde</surname><given-names>A</given-names></name><name><surname>de Mello</surname><given-names>CB</given-names></name><name><surname>Brunoni</surname><given-names>D</given-names></name><name><surname>Melaragno</surname><given-names>MI</given-names></name></person-group><article-title>Pure duplication 1q41-qter: further delineation of trisomy 1q syndromes</article-title><source>Am J Med Genet A</source><year>2008</year><volume>146A</volume><fpage>2663</fpage><lpage>2667</lpage><pub-id pub-id-type="pmid">18798309</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sireteanu</surname><given-names>A</given-names></name><name><surname>Covic</surname><given-names>M</given-names></name><name><surname>Gorduza</surname><given-names>EV</given-names></name></person-group><article-title>[Array CGH: technical considerations and applications]</article-title><source>Rev Med Chir Soc Med Nat Iasi</source><year>2012</year><volume>116</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">23077951</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamradt</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>V</given-names></name><name><surname>Wahrheit</surname><given-names>K</given-names></name><name><surname>Tolosi</surname><given-names>L</given-names></name><name><surname>Rahnenfuehrer</surname><given-names>J</given-names></name><name><surname>Schilling</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Stoeckle</surname><given-names>M</given-names></name><name><surname>Meltzer</surname><given-names>P</given-names></name><etal/></person-group><article-title>Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e769</fpage><pub-id pub-id-type="pmid">17712417</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuutila</surname><given-names>S</given-names></name><name><surname>Aalto</surname><given-names>Y</given-names></name><name><surname>Autio</surname><given-names>K</given-names></name><name><surname>Bj&#x000f6;rkqvist</surname><given-names>AM</given-names></name><name><surname>El-Rifai</surname><given-names>W</given-names></name><name><surname>Hemmer</surname><given-names>S</given-names></name><name><surname>Huhta</surname><given-names>T</given-names></name><name><surname>Kettunen</surname><given-names>E</given-names></name><name><surname>Kiuru-Kuhlefelt</surname><given-names>S</given-names></name><name><surname>Larramendy</surname><given-names>ML</given-names></name><etal/></person-group><article-title>DNA copy number losses in human neoplasms</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">10487825</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nessling</surname><given-names>M</given-names></name><name><surname>Solinas-Toldo</surname><given-names>S</given-names></name><name><surname>Wilgenbus</surname><given-names>KK</given-names></name><name><surname>Borchard</surname><given-names>F</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name></person-group><article-title>Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2</article-title><source>Genes Chromosomes Cancer</source><year>1998</year><volume>23</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">9824203</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JU</given-names></name><name><surname>Kang</surname><given-names>JJ</given-names></name><name><surname>Kwon</surname><given-names>KC</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Jeong</surname><given-names>TE</given-names></name><name><surname>Noh</surname><given-names>SM</given-names></name><name><surname>Koo</surname><given-names>SH</given-names></name></person-group><article-title>Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization</article-title><source>J Korean Med Sci</source><year>2006</year><volume>21</volume><fpage>656</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">16891809</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YQ</given-names></name><name><surname>Zhu</surname><given-names>ZG</given-names></name><name><surname>Liu</surname><given-names>BY</given-names></name><name><surname>Chen</surname><given-names>XH</given-names></name><name><surname>Yin</surname><given-names>HR</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name></person-group><article-title>[Chromosomal alterations analyzed by comparative genomic hybridization in primary gastric carcinoma]</article-title><source>Zhonghua Wei Chang Wai Ke Za Zhi</source><year>2007</year><volume>10</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">17380459</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>B</given-names></name><name><surname>Dachrut</surname><given-names>S</given-names></name><name><surname>Coral</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Chu</surname><given-names>KM</given-names></name><name><surname>Law</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e29824</fpage><pub-id pub-id-type="pmid">22539939</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Imoto</surname><given-names>I</given-names></name><name><surname>Fukuda</surname><given-names>Y</given-names></name><name><surname>Pimkhaokham</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Sugano</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name></person-group><article-title>Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4735</fpage><lpage>4739</lpage><pub-id pub-id-type="pmid">10987278</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Attias</surname><given-names>R</given-names></name><name><surname>Aurias</surname><given-names>A</given-names></name><name><surname>P&#x000e9;rot</surname><given-names>G</given-names></name><name><surname>Burel-Vandenbos</surname><given-names>F</given-names></name><name><surname>Otto</surname><given-names>J</given-names></name><name><surname>Venissac</surname><given-names>N</given-names></name><name><surname>Pedeutour</surname><given-names>F</given-names></name></person-group><article-title>Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C</article-title><source>Cancer Genet Cytogenet</source><year>2006</year><volume>167</volume><fpage>122</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">16737911</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Dombkowski</surname><given-names>A</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Martin-Trevino</surname><given-names>R</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Ethier</surname><given-names>SP</given-names></name><name><surname>Yang</surname><given-names>ZQ</given-names></name></person-group><article-title>Identification and functional analysis of 9p24 amplified genes in human breast cancer</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">21666724</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towle</surname><given-names>R</given-names></name><name><surname>Tsui</surname><given-names>IF</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>MacLellan</surname><given-names>S</given-names></name><name><surname>Poh</surname><given-names>CF</given-names></name><name><surname>Garnis</surname><given-names>C</given-names></name></person-group><article-title>Recurring DNA copy number gain at chromosome 9p13 plays a role in the activation of multiple candidate oncogenes in progressing oral premalignant lesions</article-title><source>Cancer Med</source><year>2014</year><volume>3</volume><fpage>1170</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">25060540</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarhadi</surname><given-names>VK</given-names></name><name><surname>Lahti</surname><given-names>L</given-names></name><name><surname>Scheinin</surname><given-names>I</given-names></name><name><surname>Ellonen</surname><given-names>P</given-names></name><name><surname>Kettunen</surname><given-names>E</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Scotlandi</surname><given-names>K</given-names></name><name><surname>Picci</surname><given-names>P</given-names></name><name><surname>Knuutila</surname><given-names>S</given-names></name></person-group><article-title>Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias</article-title><source>Genes Chromosomes Cancer</source><year>2014</year><volume>53</volume><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">24664538</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>CL</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Savarese</surname><given-names>DM</given-names></name><name><surname>Savarese</surname><given-names>TM</given-names></name></person-group><article-title>Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma</article-title><source>Am J Pathol</source><year>2001</year><volume>158</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11141475</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiessling</surname><given-names>S</given-names></name><name><surname>Muller-Newen</surname><given-names>G</given-names></name><name><surname>Leeb</surname><given-names>SN</given-names></name><name><surname>Hausmann</surname><given-names>M</given-names></name><name><surname>Rath</surname><given-names>HC</given-names></name><name><surname>Strater</surname><given-names>J</given-names></name><name><surname>Spottl</surname><given-names>T</given-names></name><name><surname>Schlottmann</surname><given-names>K</given-names></name><name><surname>Grossmann</surname><given-names>J</given-names></name><name><surname>Montero-Julian</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>10304</fpage><lpage>10315</lpage><pub-id pub-id-type="pmid">14701802</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurita</surname><given-names>AJ</given-names></name><name><surname>Troncoso</surname><given-names>P</given-names></name><name><surname>Card&#x000f3;-Vila</surname><given-names>M</given-names></name><name><surname>Logothetis</surname><given-names>CJ</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name></person-group><article-title>Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">14744752</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanavadi</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>TA</given-names></name><name><surname>Watkins</surname><given-names>G</given-names></name><name><surname>Mansel</surname><given-names>RE</given-names></name><name><surname>Jiang</surname><given-names>WG</given-names></name></person-group><article-title>Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer</article-title><source>Ann Surg Oncol</source><year>2006</year><volume>13</volume><fpage>802</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">16614887</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Yoshizaki</surname><given-names>A</given-names></name><name><surname>Izumida</surname><given-names>S</given-names></name><name><surname>Suehiro</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Uemura</surname><given-names>T</given-names></name><name><surname>Yakata</surname><given-names>Y</given-names></name><name><surname>Shichijo</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Sekin</surname><given-names>I</given-names></name></person-group><article-title>Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells</article-title><source>Int J Oncol</source><year>2007</year><volume>30</volume><fpage>825</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">17332920</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>VO</given-names></name><name><surname>Ozawa</surname><given-names>MG</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Shintani</surname><given-names>T</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name></person-group><article-title>The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>1995</fpage><lpage>1999</lpage><pub-id pub-id-type="pmid">19244100</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name></person-group><article-title>Interleukin-11 receptor &#x003b1; is overexpressed in human osteosarcoma, and near-infrared-labeled IL-11R&#x003b1; imaging agent could detect osteosarcoma in mouse tumor xenografts</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><fpage>2369</fpage><lpage>2375</lpage><pub-id pub-id-type="pmid">25524575</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwertschlag</surname><given-names>US</given-names></name><name><surname>Trepicchio</surname><given-names>WL</given-names></name><name><surname>Dykstra</surname><given-names>KH</given-names></name><name><surname>Keith</surname><given-names>JC</given-names></name><name><surname>Turner</surname><given-names>KJ</given-names></name><name><surname>Dorner</surname><given-names>AJ</given-names></name></person-group><article-title>Hematopoietic, immunomodulatory and epithelial effects of interleukin-11</article-title><source>Leukemia</source><year>1999</year><volume>13</volume><fpage>1307</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">10482979</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teramura</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Yoshinaga</surname><given-names>K</given-names></name><name><surname>Iwabe</surname><given-names>K</given-names></name><name><surname>Mizoguchi</surname><given-names>H</given-names></name></person-group><article-title>Effect of interleukin 11 on normal and pathological thrombopoiesis</article-title><source>Cancer Chemother Pharmacol</source><year>1996</year><volume>38 Suppl</volume><fpage>S99</fpage><lpage>S102</lpage><pub-id pub-id-type="pmid">8765427</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marie</surname><given-names>SK</given-names></name><name><surname>Okamoto</surname><given-names>OK</given-names></name><name><surname>Uno</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>AP</given-names></name><name><surname>Oba-Shinjo</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name><name><surname>Camargo</surname><given-names>AA</given-names></name><name><surname>Kosoy</surname><given-names>A</given-names></name><name><surname>Carlotti</surname><given-names>CG</given-names></name><name><surname>Toledo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">17960622</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>LG</given-names></name><name><surname>Kornblum</surname><given-names>HI</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name></person-group><article-title>Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers</article-title><source>Mol Cancer Ther</source><year>2014</year><volume>13</volume><fpage>1393</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">24795222</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Deluca</surname><given-names>AM</given-names></name><name><surname>Alani</surname><given-names>RM</given-names></name></person-group><article-title>Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e594</fpage><pub-id pub-id-type="pmid">17611626</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickard</surname><given-names>MR</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Hedge</surname><given-names>VL</given-names></name><name><surname>Mourtada-Maarabouni</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>GT</given-names></name></person-group><article-title>Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer</article-title><source>Breast Cancer Res</source><year>2009</year><volume>11</volume><fpage>R60</fpage><pub-id pub-id-type="pmid">19671159</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuner</surname><given-names>R</given-names></name><name><surname>F&#x000e4;lth</surname><given-names>M</given-names></name><name><surname>Pressinotti</surname><given-names>NC</given-names></name><name><surname>Brase</surname><given-names>JC</given-names></name><name><surname>Puig</surname><given-names>SB</given-names></name><name><surname>Metzger</surname><given-names>J</given-names></name><name><surname>Gade</surname><given-names>S</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>G</given-names></name><name><surname>Bartsch</surname><given-names>G</given-names></name><name><surname>Steiner</surname><given-names>E</given-names></name><etal/></person-group><article-title>The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer</article-title><source>J Mol Med (Berl)</source><year>2013</year><volume>91</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">22945237</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway</article-title><source>Mol Cancer</source><year>2014</year><volume>13</volume><fpage>100</fpage><pub-id pub-id-type="pmid">24885567</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>D</given-names></name><name><surname>Jubb</surname><given-names>AM</given-names></name><name><surname>Hogue</surname><given-names>D</given-names></name><name><surname>Dowd</surname><given-names>P</given-names></name><name><surname>Kljavin</surname><given-names>N</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name><name><surname>Frantz</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>9751</fpage><lpage>9761</lpage><pub-id pub-id-type="pmid">16266996</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><article-title>MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells</article-title><source>Cell Cycle</source><year>2013</year><volume>12</volume><fpage>1655</fpage><lpage>1656</lpage><pub-id pub-id-type="pmid">23673321</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minata</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Joshi</surname><given-names>K</given-names></name><name><surname>Nakano-Okuno</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>CH</given-names></name><name><surname>Kornblum</surname><given-names>HI</given-names></name><name><surname>Molla</surname><given-names>A</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name></person-group><article-title>Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e92546</fpage><pub-id pub-id-type="pmid">24739874</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>R</given-names></name><name><surname>Mohyeldin</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>J</given-names></name><name><surname>Kornblum</surname><given-names>HI</given-names></name><name><surname>Beullens</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name></person-group><article-title>MELK-a conserved kinase: functions, signaling, cancer, and controversy</article-title><source>Clin Transl Med</source><year>2015</year><volume>4</volume><fpage>11</fpage><pub-id pub-id-type="pmid">25852826</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Xing</surname><given-names>XF</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>XZ</given-names></name><name><surname>Ji</surname><given-names>JF</given-names></name></person-group><article-title>Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>6266</fpage><lpage>6280</lpage><pub-id pub-id-type="pmid">26701722</pub-id></element-citation></ref></ref-list></back></article>